Qiagen NV - QGEN Net Assets per Single Share

Graphic logo of Qiagen N.V. (QGEN)

Qiagen N.V. dominates the molecular testing segment, leveraging a massive installed base of equipment to protect against dumping. The BVPS trend demonstrates a stable plateau, while the 16.23 value reflects the balance of the book value per share metric. Business resilience is driven by the non-cyclical demand for DNA analysis, and broad diversification between forensics and medicine guarantees a steady stream of profit.

Qiagen Group (QGEN) Equity per Share: for the period 07/04/2022 - 10/28/2026
Manufactured products of Qiagen

Book value per share reflects the issuer's net assets divided by the number of outstanding shares. Professionals utilize this indicator to determine the intrinsic value of a business, independent of market speculation. By analyzing fluctuations in the book value of a single security, an investor assesses the company's actual asset stability. For Qiagen N.V. (QGEN), this parameter confirms capitalization driven by the ownership of molecular diagnostics technologies. Steady growth of this metric is supported by regular revenues from the sale of high-margin consumables.

Competitors of Qiagen N.V. (QGEN)

TEM (Tempus AI, Inc.) - Book Value per Share|IONS: Net Asset Value per Share|Net Assets per Single Share Repligen Corporation|aviditybiosciences.com (RNA) - Equity per Share|Book Value per Share CRISPR Therapeutics (CRSP)|Equity per Share WGS|Net Assets per Single Share Ultragenyx Pharma RARE|Equity per Share Beam Tx (BEAM)|Book Value per Share SRPT (Sarepta Therapeutics, Inc.)|twistbioscience.com - Book Value per Share|Net Assets per Single Share TXG|NTLA - Book Value of One Share|Stoke - Book Value per Share|BioLife (BLFS) - Net Assets per Share|WVE (Wave Life Sciences) - Book Value per Share|Book Value per Share mazetx.com|SION: Book Value per Share|Book Value of One Share Prime Medicine Inc (PRME)|TSHA: Book Value per Share|uniQure Pharma - Net Asset Value per Share|MeiraGTx Holdings plc (MGTX) - Net Assets per Single Share|regenxbio.com (RGNX) - Equity per Share|Accounting Value per Share Solid Biosciences SLDB|OCGN (Ocugen Inc) - Accounting Value of a Share|Net Assets per Single Share Pacific Biosciences of California (PACB)|Equity per Share Benitec Corp (BNTC)|DSGN (Design Therapeutics) - Accounting Value per Share|Net Assets per Share rocketpharma.com RCKT|Accounting Value per Share 4D Molecular Therapeutics, Inc. FDMT|LXEO - Net Assets per Single Share|Accounting Value per Share KRRO (Korro Bio, Inc)|EDIT: Net Assets per Share|Net Assets per Single Share SLN (Silence Therapeutics)|ProQR Therapeutics (PRQR) - Book Value of One Share|Codexis Inc - Book Value per Share|Book Value of One Share Sangamo Therapeutics Inc.|Nautilus Biotechnology - Book Value per Share|Net Asset Value per Share MGX (Metagenomi Therapeutics)|DTIL - Net Assets per Single Share|Equity per Share Generation Bio Co GBIO|Boundless Bio (BOLD) - Book Value per Share|XCUR: Equity per Share|Net Assets per Single Share imunon.com|Phio Pharmaceuticals Corp. (PHIO) - Equity per Share|MBIO (Mustang Bio Inc) - Book Value per Share|Book Value per Share RNAZ|BNGO: Net Assets per Single Share|Book Value of One Share Applied DNA Sciences Inc (APDN)|Book Value per Share BLUE|Net Assets per Share ImmunoPrecise Antibodies Ltd IPA|Omega Therapeutics - Book Value per Share|OMIC - Book Value per Share|Book Value per Share RGLS (Regulus Therapeutics Inc.)|Syros Pharmaceuticals Inc. (SYRS) - Book Value of One Share|Book Value per Share TBIO (Codex DNA)|Net Asset Value per Share TCON|Net Assets per Single Share Unity Biotechnology UBX